Biosimilar Enbrel: Sandoz, FDA Panel Bring Experience To TNF-Inhibitor Review
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Arthritis Advisory Committee will discuss Sandoz’s 351(k) application referencing Amgen's etanercept July 13.